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Abstract Growth and invasion of breast cancer require
extracellular proteolysis in order to physically restructure
the tissue microenvironment of the mammary gland. This
pathological tissue remodeling process depends on a
collaboration of epithelial and stromal cells. In fact, the
majority of extracellular proteases are provided by stromal
cells rather than cancer cells. This distinct expression
pattern is seen in human breast cancers and also in
transgenic mouse models of breast cancer. The similar
expression patterns suggest that transgenic mouse models
are ideally suited to study the role of extracellular
proteases in cancer progression. Here we give a status
report on protease intervention studies in transgenic
models. These studies demonstrate that proteases are
involved in all stages of breast cancer progression from
carcinogenesis to metastasis. Transgenic models are now
beginning to provide vital mechanistic insight that will
allow us to combat breast cancer invasion and metastasis
with new protease-targeted drugs.
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Abbreviations
CIS carcinoma in situ
DCIS ductal CIS
DMBA 7,12-dimethylbenzanthracene
ECM extracellular matrix
MMP matrix metalloprotease
MMTV mouse mammary tumor
virus long terminal
repeat promoter
PA system plasminogen activation
system
PAI-1 plasminogen activator
inhibitor-1
pKal plasma kallikrein
Plg plasminogen
PymT polyomavirus middle
T antigen
SV40-T simian virus 40 large
T antigen
TDLU terminal ductal lobular
unit
TGF-" transforming growth
factor-"
TIMP tissue inhibitor of
metalloproteases
tPA tissue plasminogen
activator
uPA urokinase plasminogen
activator
uPAR urokinase receptor
VEGF vascular endothelial
growth factor
WAP whey acidic protein
promoter
Introduction
Breast cancer progression is accompanied by increased
expression of proteases that are capable of degrading the
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e-mail: kasper@finsenlab.dkextracellular matrix (ECM) leading to cancer cell invasion
and eventually to dissemination of cancer cells to other
organs. The proteolytic capability of breast cancers is
reminiscent of the inherent proteolytic capability of the
healthy mammary gland. Extracellular proteases are neces-
sary for the dynamic tissue remodeling that takes place
during normal mammary gland development and pregnancy
cycling (reviewed in [1]). During development, the invasive
phenotype of terminal end buds is associated with a
controlled proteolytic digestion of ECM in the fat pad,
and side branching of the newly formed ducts requires a
focal degradation of basement membrane. The proliferative
response of the epithelium during pregnancy and lactation
is accompanied by limited proteolytic activity. In contrast,
the involution of the lactating gland to a resting gland after
weaning restructures the entire gland and requires extensive
degradation of ECM and basement membranes. Extracellu-
lar proteases are thus more abundant during involution than
at any other stage during development and the pregnancy
cycle. The similarity between the proteolytic repertoire of
the normal gland and the proteolytic capability of mamma-
ry cancers is best illustrated by the fact that the cellular
expression patterns of individual proteolytic components
are very alike, especially when comparing involution and
cancer [2]. In terms of extracellular proteolysis, breast
cancer in many ways resembles a mammary gland in a state
of continuous and uncontrolled tissue remodeling.
Matrix Metalloproteases and Plasminogen Activators
Two families of extracellular proteases have been exten-
sively studied in relation to mammary gland morphogenesis
and cancer. These are the matrix metalloproteases (MMPs)
and the group of serine proteases that govern the activation
of plasminogen (Plg). Figure 1 illustrates the connected
extracellular proteolytic network of the MMPs and the Plg
activation system (PA system).
The liver-derived proenzyme Plg is found in high
concentration throughout the body. In contrast, expression
of the specific urokinase- and tissue-type Plg activators
(uPA and tPA) is induced locally and thus determines where
and when Plg is converted to the active protease plasmin [3,
4]. Plasmin, activated by uPA, is important for a number of
tissue remodeling processes that, in addition to pregnancy
cycling of the mammary gland [5], include wound healing
[6] and embryo implantation [7]. In contrast, tPA is
acknowledged to be primarily involved in thrombolysis
and neurobiology [3, 4] but is also active during wound
healing [8]. A newly identified Plg activator, plasma
kallikrein (pKal), is involved in adipocyte differentiation in
the involuting mammary gland [9] and in wound healing [8].
The MMPs constitute a large family of 22 extracellular
metalloproteinases in mice (24 in humans) [10, 11] (an
updated list of human and mouse proteases is available at
http://web.uniovi.es/degradome/). MMPs are essential for a
number of physiological tissue remodeling processes during
ontogenesis and adult life, including mammary gland
development [12, 13], bone development [14], wound
healing [15], and embryo implantation [7]. During mam-
mary gland development MMP-2 is involved in ductal
elongation, and MMPs-2 and -3 are involved in ductal
branching [13]. MMP-3 is also rate limiting for adipocyte
differentiation during post-lactational involution [16]. The
ductal tree is eventually fully formed in mice that are
deficient in MMP-2, -3 or several other MMPs, indicating
that the remaining MMPs are able to replace their activity
in a functional overlap.
Several members of the MMP and PA systems are
involved in breast cancer progression. We will focus on the
role played by these extracellular protease families during
the various stages of breast cancer progression, from the
initial hyperplastic lesion to disseminated disease, with
particular emphasis on the insight gained from transgenic
mouse models.
Mouse Models of Breast Cancer
The mouse mammary gland is ideally suited to study cancer
progression for a number of reasons. First of all, there are
many similarities between the human and mouse mammary
glands (for detailed reviews see [17, 18]). Human and
mouse mammary glands contain the same epithelial cell
types: the ductal epithelial cells, luminal (milk secreting)
epithelial cells, and the myoepithelial cells. They also
contain adipose tissue and stroma, although the composi-
tion of the stroma differs between the human and mouse
glands. One of the few differences between the species is
that the epithelium in the mouse gland is surrounded by
adipose tissue and a relatively sparse stroma, whereas the
human mammary epithelium is encompassed by a special-
ized fibroblastoid stroma and is not in direct contact with
adipocytes. The epithelial structure in the mature nullipa-
rous mouse gland is also much less developed compared to
the human gland and consists only of a branching but
otherwise naked ductal tree. In contrast, the mature ductal
tree in non-pregnant women contains groups of acini at the
end of terminal ducts, named terminal ductal lobular units
(TDLU). The mouse epithelium develops similar lobuloal-
veolar structures transiently during the estrus cycle in
certain mouse strains [19] and always during early
pregnancy, and in this way the resting human gland is
structurally more similar to the pregnant mouse gland. In
84 J Mammary Gland Biol Neoplasia (2007) 12:83–97some transgenic breast cancer models, the earliest hyper-
plastic lesions may also resemble TDLU-like structures [20].
A second ideal feature of the mouse mammary gland is
that it is readily accessible for monitoring tumor growth and
for other experimental procedures. This has lead to the
development of numerous transplanted models, chemically
induced models and transgenic models. We will limit our
discussion to the transgenic and chemically induced models
since there are inherent problems of transplanted models
that may introduce bias. Depending on the study design,
these obstacles can include: (1) a species barrier between
proteolytic components supplied by the transplant and the
host (as documented for human and mouse uPA and its
receptor uPAR [21]); and (2) a cellular inconsistency with
respect to protease expression in the sense that the majority
of proteolytic components are supplied by stromal cells in
human breast cancers while epithelial-based cancer cell
lines often express the very same proteolytic components
[22]. This is presumably due to genetic alterations that have
occurred during in vitro culture. Furthermore, (3) when
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Figure 1 The PA and MMP systems in the mouse. Plasmin and
MMPs are two major sources of extracellular proteolysis. Plg is
converted to the active protease plasmin by one of three Plg activators,
uPA, tPA, and pKal. The generation of plasmin is enhanced by the
binding of uPA to the cell surface receptor uPAR, and by the binding
of tPA to coagulated fibrin or to cell surface proteins (annexin II [86]
and CKAP4 [87]). The conversion of pro-uPA to active uPA may be
initiated by several proteases, depending on the tissue in question.
Additional pro-uPA is then activated by plasmin in a positive feed-
back loop. The PA system is tightly controlled by several serine
protease inhibitors (serpins); the primary and most specific inhibitors
are the Plg activator inhibitor PAI-1 that targets uPA and tPA, and the
plasmin inhibitor α2-antiplasmin (α2AP). Major substrates of plasmin
include fibrin, fibronectin, laminin, and other ECM proteins, latent
TGF-β and other growth factors, and pro-MMPs. The 22 different
mouse MMPs are all extracellular, and are either soluble or
membrane-anchored. Like the serine proteases of the PA system, the
MMPs are also synthesized as inactive proforms that require
proteolytic activation. Ten of the 22 pro-MMPs, including the
membrane-anchored MMPs, have a furin cleavage site and may be
activated by furin-like proprotein convertases before they are secreted.
The remaining pro-MMPs are activated extracellularly, typically by
plasmin or by other MMPs. The MMP system is counterbalanced by a
group of four inhibitors, TIMPs, that have varying specificities for
individual MMPs. In addition, the membrane-anchored MMP inhib-
itor RECK regulates a subgroup of MMPs including MMPs-2, -9, and
-14 [88]. An excess of plasmin or MMP activity may ultimately be
cleared by α2-macroglobulin (α2M) which is a non-specific protease
scavenger. The MMPs are collectively able to degrade any component
of the ECM. Important substrates for the MMPs as a group include the
native fibrillar collagens and all four major components of the
basement membrane: collagen type IV, laminin, nidogen/entactin,
and heparan sulfate proteoglycans.
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transplantation, it is possible that a tumor-suppressive
phenotype in the protease-deficient host is due to an immune
response directed at the protease-producing transplant.
A third advantage of the mammary gland for cancer
research is that there are more transgenic models of
mammary cancer than for any other cancer form, primarily
because relatively specific promoters are available for
targeting oncogene expression to the mammary epithelium.
The promoters most frequently used stem from the whey
acidic protein (WAP) gene, and the mouse mammary tumor
virus long terminal repeat (MMTV). The promoters are not
equally active at all stages of mammary gland development
and the pregnancy cycle [23]. The MMTV promoter is
active during puberty but is greatly enhanced during
pregnancy. The WAP promoter is primarily active from
mid pregnancy and during lactation. Accordingly, cancer
progression is accelerated by pregnancies in most transgen-
ic models and some models only develop tumors after a
number of pregnancies.
Finally, the tumor histopathology of several transgenic
models is very similar to human breast cancers [17]. The
histopathology seen in a single mouse model is, however,
relatively uniform and often characteristic of the inducing
oncogene, and in this way no single model replicates the
variability of tumor phenotypes seen among different breast
cancer patients [17, 24]. This drawback is to be expected,
considering the fact that transgenic models rely on a well-
defined initiating oncogene in mice with a homogenous
genetic background (inbred strains). In contrast, human
breast cancers arise from combinations of multiple muta-
tions in women with heterogenous genetic backgrounds. A
notable similarity between mouse and human tumors is the
development of a reactive stroma and the appearance of
extracellular proteolysis in the tumor microenvironment.
There are, however, also significant drawbacks to the use of
transgenic models, such as the fact that they express
oncogenes in the entire mammary epithelium (or at least a
large part of it) often giving rise to multiple tumors and in
some models a general hyperplasia of the entire gland. By
contrast, human tumors derive from a single site, therefore
resulting in a single tumor in the breast.
A comprehensive list of transgenic breast cancer models
is available at http://emice.nci.nih.gov/ and has recently
been reviewed [23]. Here we will focus on models that
have been studied in relation to extracellular proteolysis.
Table 1 summarizes the studies that describe MMP or PA
system intervention in transgenic and chemically induced
breast cancer models. It is evident from Table 1 that the role
of proteases has almost exclusively been studied in models,
in which one of the four oncoproteins ErbB-2 (neu) [25],
Ras [26], Wnt1 [27], or the polyomavirus middle T antigen
(PymT) [28] are induced by the MMTV promoter. ErbB-2
is often overexpressed in human breast cancers. Ras and the
downstream effector proteins of Wnt1 and PymT are also
frequently activated in human breast cancer, although
mutation/overexpression of Ras and Wnt1 are infrequent
in breast cancer and there is no cellular counterpart of the
PymT oncogene [23]. In all four transgenic models, tumor
incidence is 100% or at least approaches 100% depending on
the time allowed for observation [29–32]. Tumor incidence
has only in a few cases [29, 32]b e e na f f e c t e di np r o t e a s e
intervention studies (Table 1). Tumor onset in the ErbB-2,
Ras, and Wnt1 models can be accelerated by multiple
pregnancies [25, 30, 32] and mice used for experiments are
frequently mated continuously, at least in the Ras and Wnt1
models [30, 32]. The PymT model is exceptionally fast even
in non-pregnant mice, where the average tumor latency is
approximately 1.5 months [31]c o m p a r e dt o4 –7m o n t h sf o r
multiparous mice in the three other models [25, 30, 32]. In
all four models the tumors metastasize primarily to the lungs
although the models differ in aggressiveness. The PymT
model is the most aggressive and the Wnt1 model the least
aggressive [31, 32]. A notable exception to the use of
transgenic models in protease studies is the chemically
induced mammary tumors that are induced by orally
administered 7,12-dimethylbenzanthracene (DMBA) with
or without hormone supplementation [33, 34]. The DMBA
model is primarily a carcinogenesis model, since the tumors
generally do not progress to form metastases [33, 34].
A feature of any transgenic model that is particularly
relevant to extracellular proteolysis is the transition from
pre-invasive (carcinoma in situ, CIS) to invasive breast
carcinoma. Most human pre-invasive lesions are ductal CIS
(DCIS), and in these lesions the carcinoma cells accumulate
in the ducts confined by the myoepithelial cell layer and the
basement membrane. Proteolytic degradation of the base-
ment membrane leads to depolarization of the myoepithelial
cells and offers the carcinoma cells access to the surround-
ing periductal stroma [35, 36]. In some human breast
carcinomas the tumor suppressive myoepithelium surround-
ing an emerging tumor can persist for a relatively long
period of time. In the MMTV-PymT model the late stage
tumors resemble human invasive ductal breast cancer, but
the myoepithelium is lost very early in tumor progression
and it is therefore a poor model of the CIS stage ([20] and
unpublished data). The lack of an intact myoepithelium, as
seen in the MMTV-PymT model, does not necessarily make
the neoplastic cells invasive. These lesions fall in the broad
category of mammary intraepithelial neoplasia (MIN),
which includes CIS-like lesions but is used more generally
in mouse tumors to describe pre-malignant epithelial cells
that have significant nuclear atypia and are surrounded by
an intact basement membrane [37]. A few transgenic breast
cancer models have been described to develop CIS lesions
with morphologic similarities to human DCIS and later
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(1)-SV40-T prostate cancer model that also develops
mammary lesions [38], the WAP-SV40-T model [39], and
the MMTV-neu models [17]. However, the CIS stage has
not been the focus of protease intervention studies so far.
Protease Expression in Transgenic Breast
Cancer Models
Extracellular proteases are generally absent in resting
mammary glands but are present as the gland undergoes
the pregnancy cycle. The levels of a number of extracellular
proteolytic components are particularly upregulated during
post-lactational mammary gland involution. These include
uPA, tPA, MMPs-2, -3, -9, -11, and their corresponding
inhibitors PAI-1 and TIMP-1 [5, 40–42]. The upregulated
proteases and protease inhibitors are presumably required
for the orderly restructuring of the lactating gland to a
virgin-like state (discussed later). During breast cancer
development, a similar proteolytic program is activated in
the diseased gland and extracellular proteases are abundant
in invasive breast cancers of both humans and mice.
Figure 2 gives a schematic comparison of the expression
patterns of MMP and PA system components in human
breast cancer and in the MMTV-PymT transgenic breast
cancer model, which has been used to analyze the
expression of several extracellular proteases. One study
used laser microdissection to isolate cancer cells and
stromal cells followed by quantitative RT-PCR to examine
the expression level of MMPs and the PA system [43]. The
study concluded that stromal tissue adjacent to cancer cells
expresses higher levels of uPA, PAI-1 and MMPs-2, -3, -11,
-13, and -14 than the cancer tissue. The predominantly
stromal expression patterns of all these components in the
MMTV-PymT model has been confirmed by in situ
hybridization [31, 43–46]. Using immunohistochemistry,
uPAR expression was found primarily in fibroblasts,
endothelial cells, and in some macrophages in the
MMTV-PymT model (unpublished data). In situ hybridiza-
tion was used in another study on MMTV-PymT tumors to
determine the expression pattern of four of the membrane-
type MMPs: the transmembrane MMPs-14, -15, and -16
and the GPI-linked MMP-17 [46]. MMPs-14 and -16 were
detected in the stroma whereas MMP-15 was the only
protease found predominantly in the epithelium. MMP-17
expression was not observed in the MMTV-PymT tumors.
The majority of these findings reflect the mRNA expression
data for human breast cancer, since uPA [47], PAI-1 [48],
and MMPs-2 [49], -3 [50], -11 [49], -13 [35], and -14 [51]
all are found predominantly in the stroma (see suppl. data to
review by Egeblad and Werb 2002 [10]). Immunoreactivity
for uPAR is also primarily found in the stroma [52].
Figure 3 provides two examples of this close correlation
between human and transgenic mouse tumors: MMP-13 is
focally expressed in stromal cells in patient material [35]
and in MMTV-PymT transgenic tumors [43] (Fig. 3c–d).
Similarly, the primary uPA inhibitor PAI-1 is expressed in
stromal cells in MMTV-PymT mice [45] and in breast
cancer patients [48]( F i g .3e–f). The PAI-1-producing
stromal cells were identified as myofibroblasts in the
human samples. It is of note that this cell type is uncommon
in the normal mouse and human glands but is abundant in
tumors from both transgenic mice (unpublished data) and
breast cancers patients [53].
Recently, the MMTV-Wnt1 model has also been used to
study the expression levels of a number of MMPs during
mammary tumor formation by RT-PCR and in situ
hybridization [32]. MMPs-2, -3, -9, -13, and -14 displayed
increased expression levels in hyperplastic glands and
mammary tumors. MMPs-2, -3, and -9 were exclusively
expressed in the stroma, while MMPs-13 and -14 were
found predominantly in the cancer cells and to a lesser
extent also in stromal cells. Again, most of these MMPs
have been reported with similar expression patterns in
human breast cancer, although MMPs-13 and -14 are
predominantly stromal in ductal breast cancer [35, 51]. It
is noteworthy that the MMTV-PymT and MMTV-Wnt1
models have broadly similar but not identical localization
and expression of MMPs.
The initial expression of proteases in human breast
cancer may be associated with the transition from DCIS to
invasive ductal carcinoma. The transition to invasive cancer
can be identified histopathologically in some DCIS lesions,
particularly facilitated by immunohistochemical staining of
myoepithelial cells and intraductal neoplastic cells. Expres-
sion studies of MMPs in human DCIS material have shown
that MMP-13 is focally upregulated in microinvasive foci
(Fig. 3b) in contrast to MMPs-2, -11, and -14, which are all
more broadly expressed in the samples [35]. All four of
these MMPs are expressed in periductal (myo)fibroblasts,
indicating an intense stromal involvement during early
invasion. Brummer et al. found that TIMP-1 is also
upregulated in areas of early invasion [54]. Mimicking the
human situation, the C3(1)-SV40-T model develops DCIS-
like lesions, in which MMP-13 is upregulated specifically
in those DCIS-like structures that show signs of invasion
(Fig. 3a). In human samples, uPA and uPAR are also
focally upregulated in areas of microinvasion together with
MMP-13, suggesting that plasmin-directed proteolysis
coincides with MMP activity in the transition to invasive
cancer [36].
Thus, the extracellular proteases expressed in transgenic
breast cancer models generally mirror those identified in
human breast cancer both in terms of expression and
localization. These findings suggest that transgenic models
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breast cancer invasion and metastasis.
Functional Studies of Proteases in Breast
Cancer Progression
Proteases in Post-lactational Mammary Gland Involution
Mammary gland involution following weaning can to some
extent be regarded as a surrogate model for the role of
proteases in breast cancer invasion due to the extensive
tissue remodeling and extracellular proteolysis taking place.
The first, reversible stage of involution is prematurely
activated in Plg-deficient mice likely due to increased milk
stasis during lactation [55]. However, the second, protease-
dependent and irreversible stage of involution seems to be
delayed in Plg-deficient mice [5]. Involution is eventually
accomplished in Plg-deficient mice probably due to
compensating action of other proteases including MMPs.
In support of this hypothesis, implantation of TIMP-1 slow
release pellets into involuting mammary glands delays
alveolar regression [40], and likewise TIMP-3 null mice
exhibit accelerated involution [56]. In contrast, transgenic
overexpression of TIMP-1 in luminal cells did not provoke
an involution phenotype [16, 57], which may be a cell-of-
origin effect since endogenous TIMP-1 is produced by
stromal cells during involution [40, 58]. Similarly, the
accelerated involution observed in mice that overexpress
MMP-3 in luminal cells [57, 59] could be an effect of
overexpressing a stromal protein in luminal cells, and is not
supported by evidence from MMP-3 null mice that do not
Figure 2 Expression of MMPs and PA components in breast tumors
in humans and in MMTV-PymT transgenic mice. MMPs and PA
components are expressed by cancer cells or stromal cells in breast
tumors or are present as ubiquitous plasma-derived proteins. The
predominant source of each mRNA/protein is illustrated for human
ductal breast cancer and for the MMTV-PymT model in mice. Only
those proteases and related components that have been analyzed in the
MMTV-PymT model are included in the comparison. Only mRNA
analyses are included except for uPAR, which was analyzed by
immunohistochemistry in both species. The “Not detected” category
includes proteases that were sporadically expressed in the tumors. The
data for the MMTV-PymT model: uPA [31]; PAI-1 [45]; uPAR,
MMPs-7, -9, -10 (unpublished data); MMPs-2, -3, -11, -13, -14, uPA,
PAI-1 [43]; MMPs-14, -15, -16, -17 [46]. The data for invasive ductal
breast cancer: uPA [47]; PAI-1 [48]; uPAR [52]; MMP-2 [49]; MMP-3
[50], MMP-7 [89]; MMP-9 [72]; MMP-10 [89]; MMP-11 [49]; MMP-
13 [35]; MMP-14 [51].
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expression in breast cancer from
transgenic mice and humans.
Expression of MMP-13 during
early invasion in mouse C3(1)-
SV40-T breast carcinoma (a)
and in human ductal carcinoma
in situ (DCIS) (b). MMP-13 is
focally expressed in periductal
fibroblast-like cells (arrows in a,
a’, and b’) in areas with early
cancer cell invasion (inv) and is
not expressed in adjacent non-
invasive areas with in situ car-
cinoma (CIS). Expression of
MMP-13 in invasive MMTV-
PymT carcinoma (c) and in
human invasive ductal carcino-
ma (IDC) of the breast (d).
Focal expression of MMP-13 is
seen in fibroblast-like cells lo-
cated in the stroma surrounding
invasive cancer cells in both
mouse and human breast cancers
(arrows in c and d). Expression
of PAI-1 in invasive MMTV-
PymT carcinoma (e) and in
human IDC of the breast (f).
The expression of PAI-1 is seen
in fibroblast-like cells located in
the stroma surrounding invasive
cancer cells in both the mouse
and human breast cancers
(arrows in e and f). All panels
are in situ hybridization using
35S-labeled probes. Panels a,
c–f are counterstained with
haematoxylin and eosin,
whereas b is combined with
pan-cytokeratin immunohisto-
chemistry and (b’) with CK14
immunohistochemistry for
myoepithelial cells [35].
Bars: a,c, 200 μm; b, 100 μm;
d–f, 150 μm.
J Mammary Gland Biol Neoplasia (2007) 12:83–97 91show a change in mammary apoptosis [16, 57]. The fact
that the PA system and the MMPs are required for the
controlled tissue remodeling of the involuting mammary
gland, suggests that it is the inherent proteolytic repertoire
of the mammary gland that is reactivated in breast cancers.
Proteases in Hyperplasia and Carcinogenesis
The earliest stages of mammary carcinogenesis including
the initial genetic alterations in the epithelial cells were
previously considered to be independent of the surrounding
stroma and extracellular proteolysis. It now seems that the
structural integrity of the stroma is an essential factor in
preventing carcinogenesis [60]. In fact, disruption of the
ECM and cellular microenvironment caused by over-
expression of MMPs-3, -7 or -14 in the mammary gland
is sufficient to initiate mammary epithelial hyperplasia [29,
61–63]. Transgenic mice overexpressing MMP-3 or MMP-
14 even develop tumors in the absence of a transgene-
supplied oncogene, and a fraction of the tumors undergo
malignant transformation [62, 63]. Similar transgenic over-
expression of Plg activators has not been reported for the
mammary gland, but a K14-uPA/uPAR double transgene
elicits extensive skin hyperplasia [64]. The MMP trans-
genes all direct MMP expression to the mammary epithe-
lium, using either MMTVor WAP promoters. Only MMP-7
is expressed by normal mammary epithelium [65], while
MMPs-3 and -14 are expressed by the mammary stroma
during development and in the mature gland [46, 61]. Thus,
tumor growth and malignancy have only been reported in
cases where extracellular proteases were expressed by cells
that would not normally produce them. Nevertheless,
ectopically expressed proteases act as independent tumor
promoters, presumably by compromising the growth-
inhibitory role of the stroma, and eventually lead to genetic
instability as if they were conventional oncogenes.
In light of the independent tumorigenic ability of some
MMP transgenes, it is not surprising that tumor onset in
transgenic breast cancer models is promoted by increased
MMP activity and delayed by decreased MMP activity in
some studies (Table 1). Tumor onset is thus promoted by
MMP-7 overexpression in the MMTV-neu model [29] and
delayed by MMP-11 deficiency in the MMTV-ras model
[30] or by TIMP-2 overexpression in the MMTV-Wnt1
model [32]. Similarly, the incidence of DMBA-induced
mammary tumors is reduced in MMP-11-deficient [66] and
in TIMP-1-overexpressing mice [34]. The results of two
studies were inconsistent with the general finding: MMP-3
overexpression resulted in reduced rather than increased
tumor incidence in the DMBA model [33], and MMP-9
deficiency led to increased tumorigenesis in the MMTV-
neu model [67]. This suggests that some MMPs may have a
protective function in mammary tumorigenesis, similar to
the protective role of MMP-8 in chemical carcinogenesis of
the skin [68].
In contrast to the documented influence of some of the
MMPs on tumor initiation, the PA system (including
genetic deficiency in Plg [44], uPA [31], PAI-1 [45], or
uPAR [unpublished data]) does not affect tumor onset in the
MMTV-PymT model. Neither does TIMP-1 overexpression
[34] or genetic deficiencies of MMPs-2, -7, -9 (Fingleton
and Matrisian, personal communication) or MMP-13
(unpublished data) in the MMTV-PymT model. At present
it is difficult to determine whether these differences reflect
the nature of the different proteases or perhaps that the very
early tumor onset, which takes place during puberty in the
MMTV-PymT model, is less sensitive to the proteolytic
environment.
Proteases in Tumor Growth and Vascularization
Mammary hyperplasias and CIS lesions are generally
supplied with oxygen and nutrients by the pre-existing
vasculature of the mammary gland. Tumor expansion
beyond a certain stage requires the formation of new blood
vessels. Angiogenesis, the sprouting of new vessels from
existing vasculature, depends on proteolytic dissection of
the endothelial basement membrane and other ECM
components. Endothelial cells penetrate a newly deposited
fibrin-rich matrix and use it as a temporary scaffold for
vessel structure [69]. Accordingly, the fibrinolytic capacity
of the PA system is crucial for vascularization in certain
experimental settings, and PAI-1 may play a dual role as a
protease inhibitor and cell migration mediator [3]. In
tumors from breast cancer patients, endothelial cells are a
considerable source of uPA, PAI-1 and uPAR suggesting a
possible role in vascularization [47, 48, 52]. This has not
been experimentally confirmed in transgenic tumors thus
far (Table 1). In the MMTV-PymT model, tumors grow
equally fast in the genetic absence or presence of Plg [44],
uPA [31], PAI-1 [45] or uPAR (unpublished data),
indicating that vascularization is not rate limiting for tumor
growth in these cases. It is likely that functional redundancy
with other proteolytic components compensates for the
absence of a single component in the intact tumor. Even in
PAI-1-deficient tumors, vascular density was not signifi-
cantly different from wild type tumors [45]. It is also
possible that vascularization of spontaneous tumors can be
partially accomplished by endothelial precursor cells in a
process termed vasculogenesis that may be independent of
proteases or depend on a different subset of proteases [11].
Deficiency of MMP-9 reduces tumor growth in trans-
genic models of skin or "-cell islet tumors, most likely due
to a requirement for MMP-9 to release vascular endothelial
growth factor (VEGF) from ECM deposits in order to
activate the angiogenic response [70, 71]. In human breast
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cells and vascular pericytes, which could suggest a similar
role of MMP-9 in breast cancer vascularization [72].
However, the evidence is less clear in transgenic breast
cancer models (Table 1). Final tumor size in MMTV-PymT-
transgenic mice is not significantly affected by single gene
deficiencies of MMPs-2, -7, -9 (Fingleton and Matrisian,
personal communication), or MMP-13 (unpublished data).
Deficiency of a single MMP may be compensated by the
presence of other MMPs. In contrast, simultaneous inhibi-
tion of a number of MMPs through a liver-specific TIMP-1
transgene significantly reduced final tumor size (by 42%) in
MMTV-PymT mice [34]. Transgenic overexpression of
TIMP-2 also caused a significant reduction in tumor growth
rate and reduced the mean blood vessel size in MMTV-
Wnt1 mammary tumors, providing direct evidence for an
effect on vascularization [32]. MMP-11 may be important
at this stage, since MMP-11-deficient mice develop
significantly smaller tumors in the DMBA [66]a n d
MMTV-ras [30] models. Surprisingly, a broad spectrum
MMP inhibitor (galardin) only resulted in a 50% reduction
in final tumor size in the MMTV-PymT model (unpub-
lished data). It is possible that some MMPs promote while
others inhibit tumor growth and vascularization, and the net
effect of inhibiting a whole range of MMPs is rather
limited. A protective role against tumor growth and
vascularization has been observed in non-mammary models
for MMP-3 [73] and MMP-19 [74].
Proteases in Cancer Metastasis
In order to successfully form metastases, cancer cells must
enter the lymphatic system or the bloodstream, survive in
circulation and arrest in the vasculature, extravasate and
finally be able to proliferate in the new tissue. There are
several metastasizing transgenic models, but the majority of
models metastasize rather infrequently and only when the
primary tumors are quite large. In addition to the MMTV-
PymT [28] and MMTV-neu [25] models, very few other
breast cancer models metastasize sufficiently to allow
rigorous quantification (reviewed in [75]). Metastasis can
be greatly accelerated by combining e.g. an MMTV-neu
model with a second mammary-specific transgene for
VEGF or transforming growth factor-"1 (TGF"1) [75–77],
but these models require more elaborate breeding. Proteases
are intimately associated with metastasis. A classic example
is the osteolytic bone metastases that are so frequent in
breast cancer patients. Breast cancer cells and the resident
osteoclasts stimulate each other in a feed-back activation
loop. Cancer cells stimulate MMP-dependent degradation
of the collagen type I rich bone matrix by osteoclasts [78,
79]. As a consequence of bone lysis, latent growth factors
are released from their deposits within the bone ECM, and
are available to stimulate further cancer cell proliferation.
Unfortunately, transgenic models generally metastasize to
the lungs and in this way the models do not exactly mimic
the organ preference of metastatic breast cancer in humans.
The PA system plays a unique role in metastasis at least
in the MMTV-PymT model that metastasizes to the lungs
[28] and lymph nodes [31] (Table 1). uPA [31], PAI-1 [45],
and uPAR (unpublished data) are all expressed both in the
primary tumor and in the lung metastases. Metastasis is
significantly reduced in both Plg-deficient and uPA-deficient
mice, while these gene deficiencies have no significant effect
on the primary MMTV-PymT tumors [31, 44]. Absence of
the specific uPA inhibitor PAI-1 has a slight metastasis-
promoting effect, but the difference is not significant
perhaps due to the presence of alternative uPA inhibitors
[45]. Deficiency of uPAR does not significantly affect
metastasis in the inbred FVB strain (unpublished data).
Plg and uPA may promote metastasis due to their
fibrinolytic ability. Fibrin-deficient mice have not been
studied in a transgenic model, but they are less susceptible
to spontaneous metastasis from transplanted tumors [80] and
lung colonization by tail vein-injected cells [81], suggesting
that fibrin is important for sustained adhesion of circulating
cancer cells in the target organ. Thus, metastasis may
depend on an intact and balanced system of fibrin formation
and fibrinolysis. Alternatively, Plg and uPA may promote
metastasis by releasing growth factors from the ECM.
Overexpression of relevant ECM-sequestered growth fac-
tors promotes breast cancer progression and metastasis in
transgenic models [76, 77, 82, 83]. These growth factors
include the possible plasmin substrates VEGF, TGFβ, and
FGF (fibroblast growth factor), as well as the possible uPA
substrate HGF (hepatocyte growth factor).
There is also considerable evidence linking the MMPs to
invasion and metastasis (reviewed in [10, 84]). In MMTV-
PymT mice treated with the broad spectrum MMP inhibitor
galardin, the average lung metastasis volume is reduced by
approximately 99%, in the context of primary tumors that
are only reduced by half (unpublished data). Metastasis
incidence is also reduced in MMTV-PymT mice that
overexpress TIMP-1 through a liver-specific transgene,
but the reduction is less pronounced and is absent with a
mammary gland-specific TIMP-1 transgene [34]. It will
take a considerable effort to define which MMPs are
responsible for the metastasis reduction observed with
these inhibitors. MMP-9 deficiency results in reduced
metastasis in the MMTV-PymT model, although this
phenotype was mouse strain dependent (Fingleton and
Matrisian, personal communication). Deficiency of MMP-2,
which is abundantly expressed in the stroma of MMTV-
PymT tumors [43], also results in reduced metastasis in the
same model (Fingleton and Matrisian, personal communi-
cation). MMPs-2 and -9 have previously been associated
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contrast, there is no effect on metastasis in MMTV-PymT
mice that are deficient in either MMP-7 (Fingleton and
Matrisian, personal communication) or MMP-13 (unpub-
lished data). Similarly, overexpression of MMP-7 in
mammary glands has no effect on lung metastasis in the
MMTV-neu model [29].
MMP-11 may play an unexpected role in actually
preventing metastasis. In the MMTV-ras model, MMP-11
deficiency results in a higher number of metastases despite
a lower number and volume of primary tumors [30].
Apparently, the transition to invasive carcinoma is greatly
accelerated in the MMP-11 null mice, indicative of a
protective function of MMP-11. A similar protective role
against metastasis has been reported in non-mammary
models for MMP-3 [73] and MMP-12 [85]. Thus, while
the general MMP inhibitor galardin has a large inhibitory
effect on metastasis, several single MMP knock-out studies
report no effect or even the opposite effect on metastasis in
breast cancer models. This demonstrates the potential of
MMP inhibitors in preventing spontaneous metastasis but
also underlines the necessity of evaluating a second
generation of MMP inhibitors for clinical trials that are
more specific than previous compounds. Transgenic models
with a well-characterized involvement of MMPs in metas-
tasis could be a useful tool in testing such compounds.
Conclusion and Future Perspectives
Transgenic breast cancer models are invaluable research
tools because they recapitulate the entire process from the
initial genetic events in normal cells to metastatic disease.
Furthermore, the very similar expression patterns of
extracellular proteases in human and mouse breast cancer
samples suggest that transgenic mouse models are ideally
suited to study the role of proteases in carcinogenesis and
the progression to invasion and metastasis.
We have only begun to examine gene deficiencies and
transgenic overexpression of the various PA and MMP
components in transgenic models. The studies that have
been performed so far suggest that no single MMP or PA
system component is likely to be all-important for any stage
in tumor progression. Practically all of the protease
intervention studies report partial phenotypes such as
delayed carcinogenesis, slower tumor growth or reduced
metastasis, if they report any phenotype at all. The absence
of any absolute phenotypes, such as prevention of metas-
tasis, suggests that many of the proteases have mutually
overlapping functions. The challenge for developing novel
therapeutics in the future will be to identify those proteases
that can be targeted simultaneously to obtain a synergistic
tumor-suppressive effect.
Another area that has so far only been thoroughly
examined in one or two transgenic models is the expression
patterns of proteases. Using protease array data, it may be
possible to draw some more detailed parallels between
individual mouse models and certain histopathological
subtypes of human breast cancers. It is very possible that
the collective of transgenic breast cancer models available,
rather than any single transgenic, will be needed to
adequately model the heterogenous human disease. Another
open question is whether certain proteases or inhibitors are
up- or downregulated in response to certain gene deficien-
cies. This may provide vital information on functional
overlap between individual proteases.
Transgenic breast cancer mice may prove to be very
reliable models not only for basic research but also for testing
experimental anti-proteolytic therapeutics, due to the high
degree of similarity with human breast cancer. However, the
transgenic models also present some significant challenges. A
key issue is that the experimental drug has to cross-react with
the mouse version of the protease. Therefore, it may be
necessary in some cases to develop two drugs in parallel, one
for each species. Due to the extracellular nature of the PA and
MMPsystems,theserepresentexcellenttargetsfortherapeutic
monoclonal antibodies. An elegant method for targeting
extracellular proteases in transgenic mice is the development
of monoclonal anti-mouse antibodies by immunizing prote-
ase-deficient mice with the target protease. In conclusion,
transgenic breast cancer models will further the identification
of extracellular proteases critical to cancer invasion and
metastasis, and aid the development of new agents against
the spread of cancer.
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